

Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)

<https://neurodegenerationresearch.eu/survey/cognition-and-obstructive-sleep-apnea-in-parkinsons-disease-effect-of-positive-airway-pressure-therapy-cope-pap-trial/>

Principal Investigators

Kaminska, Marta

Institution

Research Institute of the McGill University Health Centre

Contact information of lead PI

Country

Canada

Title of project or programme

Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)

Source of funding information

CIHR

Total sum awarded (Euro)

€ 300,385

Start date of award

01/07/2014

Total duration of award in years

4

Keywords

Research Abstract

Cognitive dysfunction (impaired memory, thinking, etc) frequently occurs in Parkinson's disease (PD), often progresses to dementia, and profoundly affects quality of life. Obstructive sleep apnea (OSA) is a common disorder in the general population that is treatable with positive airway pressure (PAP) therapy. It is known to impair cognitive function, but whether treatment improves cognitive function is less clear. When already affected by a degenerative process like

PD, the brain might be more vulnerable to the effects of OSA, and more responsive to OSA treatment. To date, OSA has not been recognized as a significant factor in PD. In preliminary work in PD patients, we have found an association between OSA and poor cognition, and cognitive improvement with PAP therapy. We now wish to more rigorously evaluate the effect of OSA treatment on cognitive function in PD in a randomized controlled trial. Our primary objective is to assess, in PD patients with OSA and cognitive deficit, the effect of CPAP therapy on global cognitive function. We will also assess other non-motor symptoms of PD, quality of life, and specific domains of neurocognitive function. PD patients will be recruited from the McGill Movement Disorders Clinic and other Quebec Parkinson Network Centres. Participants will need to have evidence of cognitive deficit and presence of OSA on screening diagnostic polysomnography (sleep study). Ninety subjects will be randomly assigned to PAP or nasal dilator strips. Detailed neuropsychological testing and other measurements (including quality of life) will be done at baseline, 3 months and 6 months. At the end of the study period, subjects will have polysomnography on their respective treatment to assess efficacy with respect to OSA treatment. This study may demonstrate that a non-pharmacologic intervention has the potential to have a marked beneficial impact on cognitive function and quality of life in a significant proportion of PD patients

Further information available at:

Types:

Investments < €500k

Member States:

Canada

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A